Radiosensitization of noradrenaline transporterexpressing tumour cells by proteasome inhibitors and the role of reactive oxygen species

EJNMMI Research

Volumn 3, Issue 1, 2013, Pages 1-10

  Rae, Colin ^a   Tesson, Mathias ^a   Babich, John W ^b   Boyd, Marie ^c   Mairs, Robert J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Bortezomib; Neuroblastoma; Proteasome; Radiosensitizer

Indexed keywords

(3 IODOBENZYL) GUANIDINE; BORTEZOMIB; IODINE 131; NORADRENALIN TRANSPORTER; PROTEASOME INHIBITOR; REACTIVE OXYGEN METABOLITE; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; TUMOR VOLUME;

EID: 84891443437     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-3-73     Document Type: Article

References (42)

1. Leung A, Shapiro B, Hattner R, Kim E, de Kraker J, Ghazzar N, Hartmann O, Hoefnagel CA, Jamadar DA, Kloos R, Lizotte P, Lumbroso J, Rufini V, Shulkin BL, Sisson JC, Thein A, Troncone L: Specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med 1997, 38:1352-1357.
2. Mairs RJ, Boyd M: Preclinical assessment of strategies for enhancement of metaiodobenzylguanidine therapy of neuroendocrine tumors. Semin Nucl Med 2011, 41:334-344.
3. 131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter. Clin Cancer Res 2005, 11:7929-7937.
4. 131I]metaiodobenzylguanidine and topotecan in combination. Br J Radiol 2008, 81:S28-35.
5. 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter. J Nucl Med 2012, 53:1146-1154.
6. Rae C, Tesson M, Babich JW, Boyd M, Sorensen A, Mairs RJ: The role of copper in disulfiram-induced toxicity and radiosensitization of cancer cells. J Nucl Med 2013, 54:953-960.
7. Kumatori A, Tanaka K, Inamura N, Sone S, Ogura T, Matsumoto T: Abnormally high expression of proteasomes in human leukemic cells. Proc Natl Acad Sci USA 1990, 87:7071-7075.
8. Ciechanover A: The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 1998, 17:7151-7160.
9. Richardson PG, Hideshima T, Anderson KC: Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003, 10:361-369.
10. Tsang PS, Cheuk AT, Chen QR, Song YK, Badgett TC, Wei JS, Khan J: Synthetic lethal screen identifies NF-κB as a target for combination therapy with topotecan for patients with neuroblastoma. BMC Cancer 2012, 12:101-110.
11. Miller CP, Ban K, Dujka ME, McConkey DJ, Munsell M, Palladino M, Chandra J: NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROSdependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007, 110:267-277.
12. Jacquemont C, Taniguchi T: Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res 2007, 67:7395-7405.
13. Ling YH, Liebes L, Jiang JD, Holland JF, Elliott PJ, Adams J, Muggia FM, Perez-Soler R: Mechanisms of proteasome inhibitor PS-341-induced G2-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003, 9:1145-1154.
14. Chen D, Dou QP: The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention. Curr Protein Pept Sci 2010, 11:459-470.
15. Russo SM, Tepper JE, Baldwin AS Jr, Liu R, Adams J, Elliott P, Cusack JC Jr: Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-κB. Int J Radiat Oncol Biol Phys 2001, 50:183-193.
16. Kamer S, Ren Q, Dicker AP: Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341). Arch Gynecol Obstet 2009, 279:41-46.
17. Berenson JR, Yellin O, Patel R, Duvivier H, Nassir Y, Mapes R, Abaya CD, Swift RA: A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 2009, 15:1069-75.
18. Roy R, Evens AM, Patton D, Gallot L, Larson A, Rademaker A, Cilley J, Spies S, Variakojis D, Gordon LI, Winter JN: Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation. Leuk Lymphoma 2013, 54:497-502.
19. Brignole C, Marimpietri D, Pastorino F, Nico B, Di Paolo D, Cioni M, Piccardi F, Cilli M, Pezzolo A, Corrias MV, Pistoia V, Ribatti D, Pagnan G, Ponzoni M: Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst 2006, 98:1142-1157.
20. Michaelis M, Fichtner I, Behrens D, Haider W, Rothweiler F, Mack A, Cinatl J, Doerr HW, Cinatl J Jr: Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo. Int J Oncol 2006, 28:439-446.
21. Cao W, Shiverick KT, Namiki K, Sakai Y, Porvasnik S, Urbanek C, Rosser CJ: Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation. World J Urol 2008, 26:509-516.
22. Pagnan G, Di Paolo D, Carosio R, Pastorino F, Marimpietri D, Brignole C, Pezzolo A, Loi M, Galietta LJ, Piccardi F, Cilli M, Nico B, Ribatti D, Pistoia V, Ponzoni M: The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response. Clin Cancer Res 2009, 15:1199-1209.
23. Maris JM, Matthay KK: Molecular biology of neuroblastoma. J Clin Oncol 1999, 17:2264-2279.
24. Blaney SM, Bernstein M, Neville K, Ginsberg J, Kitchen B, Horton T, Berg SL, Krailo M, Adamson PC: Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a children's oncology group study (ADVL0015). J Clin Oncol 2004, 22:4804-4809.
25. Cairns RA, Harris IS, Mak TW: Regulation of cancer cell metabolism. Nat Rev Cancer 2011, 11:85-95.
26. Perez-Galan P, Roue GI, Villamor N, Montserrat E, Campo E, Colomer D: The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006, 107:257-264.
27. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C: Chemotherapyinduced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 2008, 44:1507-1515.
28. 123I]MIBG. J Labelled Cpd Radiopharm 1999, 42:653-661.
29. Neshasteh-Riz A, Angerson WJ, Reeves JR, Smith G, Rampling R, Mairs RJ: Incorporation of iododeoxyuridine in multicellular glioma spheroids: implications for DNA-targeted radiotherapy using Auger electron emitters. Br J Cancer 1997, 75:493-499.
30. 131I meta-iodobenzylguanidine. Gene Ther 1999, 6:1147-1152.
31. Chou TC, Talalay P: Quantitative analysis of dose-effect relationship: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
32. Juvekar A, Manna S, Ramaswami S, Chang TP, Vu HY, Ghosh CC, Celiker MY, Vancurova I: Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB-dependent transcription and induction of apoptosis in CTCL. Mol Cancer Res 2011, 9:183-194.
33. Ding WX, Ni HM, Chen X, Yu J, Zhang L, Yin XM: A coordinated action of Bax, PUMA, and p53 promotes MG132-induced mitochondria activation and apoptosis in colon cancer cells. Mol Cancer Ther 2007, 6:1062-1069.
34. Fernandez Y, Miller TP, Denoyelle C, Esteban JA, Tang WH, Bengston AL, Soengas MS: Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death. J Biol Chem2006, 281:1107-1118.
35. Pajonk F, Pajonk K, McBride WH: Apoptosis and radiosensitization of Hodgkin cells by proteasome inhibition. Int J Radiat Oncol Biol Phys 2000, 47:1025-1032.
36. Warren G, Grimes K, Xu Y, Kudrimoti M, St Clair W: Selectively enhanced radiation sensitivity in prostate cancer cells associated with proteasome inhibition. Oncol Rep 2006, 15:1287-1291.
37. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004, 22:2108-2121.
38. Szatrowski TP, Nathan CF: Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991, 51:794-798.
39. Wu HM, Chi KH, Lin WW: Proteasome inhibitors stimulate activator protein-1 pathway via reactive oxygen species production. FEBS Lett 2002, 526:101-105.
40. Han YH, Park WH: MG132 as a proteasome inhibitor induces cell growth inhibition and cell death in A549 lung cancer cells via influencing reactive oxygen species and GSH level. Hum Exp Toxicol 2010, 29:607-614.
41. Ling YH, Liebes L, Zou Y, Perez-Soler R: Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 2003, 278:33714-33723.
42. Zanotto-Filho A, Braganhol E, Battastini AM, Moreira JC: Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling. Invest New Drugs 2012, 30:2252-2262.